Incyte | Umsatzkosten



Cost Of Sales Veränderung Datum
Acadia Pharmaceuticals USD 21.8M 2.95M 2024-12
Agios Pharmaceuticals USD 1.26M 477K 2024-12
Alnylam Pharmaceuticals USD 102.82M 16.91M 2024-12
Amgen USD 3.11B 198M 2024-12
Biogen USD 583.5M 55.2M 2024-12
BioMarin Pharmaceutical USD 136.14M 52.32M 2024-12
Bristol-Myers Squibb USD 3.21B 356M 2024-12
Eli Lilly USD 2.4B 233M 2024-12
Exelixis USD 19.96M 2.64M 2025-01
Gilead Sciences USD 1.58B 7M 2024-12
Incyte USD 82.38M 2.49M 2024-12
Ionis Pharmaceuticals USD 3.83M 2.76M 2024-12
MacroGenics USD 1.87M 953K 2024-09
Merck USD 3.71B 181M 2024-12
Moderna USD 546M 246M 2024-12
Neurocrine Biosciences USD 9.3M 1.3M 2024-12
Novartis USD 3.32B 90M 2024-12
Novartis USD 3.31B 73M 2024-12
Pfizer USD 5.65B 781M 2024-12
PTC Therapeutics USD 16.28M 5.44M 2024-12
Regeneron Pharmaceuticals USD 565.4M 74.3M 2024-12
Sarepta Therapeutics USD 132.3M 40.61M 2024-12
Ultragenyx Pharmaceutical USD 16.89M 4.13M 2024-12
Vertex Pharmaceuticals USD 423.4M 30.8M 2024-12



Incyte Umsatzkosten - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Mar 2025.